S502I

Category 3/4 — Most DruggableUncertain significanceTransmembrane · predictedSource card

Serine → Isoleucine at position 502 · Transmembrane helix 7 · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference

Wild-type S502 — hydrogen bond to L506

Fullscreen ↗

DynaMut2 mutant · S502I

Mutant I502 — hydrogen bond to P504 lost (4 contacts lost)

Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

4 lost8 gained4 preserved

Interaction type	Wild-type partner	Mutant partner	Status
Hydrogen bond	—	Q486	Gained
Hydrogen bond	P504	—	Lost
Hydrogen bond	C505	C505	Preserved
Hydrogen bond	L506	L506	Preserved
Polar contact	—	Q486	Gained
Polar contact	P504	—	Lost
Polar contact	C505	C505	Preserved
Polar contact	L506	L506	Preserved
Van der Waals	—	T487	Gained
Van der Waals	P504	—	Lost
Van der Waals	C505	—	Lost
Hydrophobic	—	T487	Gained
Hydrophobic	—	N500	Gained
Hydrophobic	—	P504	Gained
Hydrophobic	—	C505	Gained
Hydrophobic	—	P885	Gained

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG

-0.05kcal/mol

Destabilising — mild

AlphaMissense

0.980

likely pathogenic

AlphaFold pLDDT

model confidence

Schema

Cat 3/4

Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance

Review statuscriteria provided, single submitter

Associated conditionsAutosomal dominant nonsyndromic hearing loss 6; Wolfram-like syndrome; Type 2 diabetes mellitus; Wolfram syndrome 1

Population frequency (gnomAD v4)Absent from gnomAD v4

cDNA changec.1505G>T

ClinVar accessionVCV004279899

Last evaluated2025/08/18 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Full Variant Card

WFS1 Wolframin — S502I Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Serine → Isoleucine at position 502. Transmembrane helix 7. ClinVar Uncertain significance, AlphaMissense 0.980, DynaMut2 ΔΔG -0.05 kcal/mol (destabilising).

Identity

Field	Value
Variant	S502I (p.Serine502Isoleucine)
DNA change	c.1505G>T
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV004279899
Amino acid change	Serine (S) → Isoleucine (I)

Structural Context

Field	Value
AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 502	79.38 — well-folded
Domain	Transmembrane helix 7
Position context	Inside Transmembrane helix 7 · position 502 is bilayer-embedded
IDR flag	No — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 502 sits in a transmembrane helix (Transmembrane helix 7). Wolframin has eleven such helices anchoring it in the ER membrane; substitutions inside the bilayer-embedded segments can disrupt helix packing, lipid contacts, and the overall ER topology of the protein. The wild-type residue is small polar (serine — hydroxyl); the mutant is medium hydrophobic (isoleucine — branched). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

Computational Predictions

AlphaMissense

Field	Value
am_pathogenicity	0.9804
am_class	likely pathogenic
Interpretation	Likely pathogenic (threshold 0.564)

DynaMut2

Field	Value
ΔΔG (kcal/mol)	-0.05 (Destabilising)
Job ID	178092094306
Result URL	https://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092094306

Clinical Evidence

Field	Value
Classification	Uncertain significance
Review status	criteria provided, single submitter
Last evaluated	2025/08/18 00:00
Inheritance	Autosomal dominant pattern indicated by associated DFNA6/14/38 (WFS1 hearing loss 6).
WFS1 variant landscape	S502I is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

Autosomal dominant nonsyndromic hearing loss 6
Wolfram-like syndrome
Type 2 diabetes mellitus
Wolfram syndrome 1

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.05 < 2 kcal/mol (fold intact) + AlphaMissense 0.980 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.05 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.980. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.

Files in this folder

AF-O76024-F1-model_v6.pdb — AlphaFold structure
S502I_molstar_viewer.html — interactive 3D viewer (auto-highlights position 502 with ball-and-stick + neighbors within 5Å)
S502I_variant_card.md — this card (source of truth)
S502I_variant_card.html — styled printable card
S502I_dynamut2_summary.html — clean offline DynaMut2 result card
dynamut2_result.json — structured result data
dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
S502I_wildtype_interactions.pse / S502I_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the S502I PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download S502I PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.